Summary
| Direction in Lyme Disease | ↑ Elevated — higher than in the comparison group |
|---|---|
| Category | Serologic |
| Also described as | Enzyme immunoassay — tier 1 |
| Compared against | Uninfected |
| Associated symptoms | Active or past Lyme infection |
| Test type | Blood test (serum / plasma / whole blood) |
| Source | Mead et al. 2019 — doi:10.15585/mmwr.mm6832a4 |
| Condition atlas | Lyme Disease Biomarker Atlas |
Trials, interventions and tests
In clinical-trial registrations this marker maps to the outcome term Change in the ALC from Screening, INT1, FU1.3, INT2, FU2.3, FU2.4, FU2.5, and EOS. (25 registered trials use a matching outcome measure).
Clinical trials using B. burgdorferi EIA (screening) as an outcome
17 more trials reference this marker.
Commercial test availability
Lyme Disease Antibody Screen (EIA) — commercial laboratory test.
Links are for reference only; availability, specimen requirements and coverage vary by location.
Related Serologic markers in Lyme Disease
- IgG immunoblot (≥5 of 10 bands) ↑
- IgM immunoblot (≥2 of 3 bands) ↑
- C6 peptide ELISA (VisE) ↑
- Anti-VlsE antibodies ↑
- Anti-OspC antibodies ↑
- Anti-OspA antibodies ↑
- Anti-p41 (flagellin) antibodies ↑
- Synovial fluid anti-Bb antibodies ↑
Full list: Lyme Disease Biomarker Atlas.
Frequently asked questions
Is B. burgdorferi EIA (screening) high or low in Lyme Disease?
Elevated. Studies summarised in the OSMF atlas report higher B. burgdorferi EIA (screening) in Lyme Disease than in Uninfected. Source: Mead et al. 2019.
What symptoms is B. burgdorferi EIA (screening) associated with in Lyme Disease?
The cited literature associates this marker with Active or past Lyme infection. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures B. burgdorferi EIA (screening)?
It is measured as a blood test (serum / plasma / whole blood). Commercial laboratories such as LabCorp, Quest Diagnostics list an orderable assay.
Is one abnormal B. burgdorferi EIA (screening) result diagnostic of Lyme Disease?
No. No single biomarker is diagnostic of Lyme Disease. B. burgdorferi EIA (screening) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Cite this page
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.